Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 1, 2011, Pages 15-28

  Triana Baltzer, Gallen B ^a   Sanders, Rebecca L ^a   Hedlund, Maria ^a   Jensen, Kellie A ^a   Aschenbrenner, Laura M ^a   Larson, Jeffrey L ^a   Fang, Fang ^a  

^a NexBio Inc   (United States)

Author keywords

Antiviral; Haemagglutinin; Neuraminidase; Resistance; Sialic acid

Indexed keywords

FLUDASE; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; PROTEIN DAS181; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; CYTOTOXICITY; FEMALE; GENE MUTATION; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MOUSE; NONHUMAN; PHENOTYPE; RECEPTOR BINDING; VIROGENESIS; VIRUS ATTACHMENT; VIRUS VIRULENCE;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MICE; MICE, INBRED BALB C; MUTATION; ORTHOMYXOVIRIDAE INFECTIONS; PHENOTYPE; PLAQUE ASSAY; RECOMBINANT FUSION PROTEINS; SELECTION, GENETIC; SERIAL PASSAGE; VIRULENCE; VIRUS REPLICATION;

EID: 78650361202     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq387     Document Type: Article

References (62)

1. WHO. Seasonal Influenza Factsheet. http://www.who.int/mediacentre/factsheets/fs211/en/index.html (12 July 2010, date last accessed).
2. Dharan NJ, Gubareva LV, Meyer JJ et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301: 1034-41.
3. Hatakeyama S, Sugaya N, Ito M et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297: 1435-42.
4. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176: 119-30.
5. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 2005; 353: 2633-6.
6. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360: 953-6.
7. Sheu TG, Deyde VM, Okomo-Adhiambo M et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52: 3284-92.
8. Suzuki H, Saito R, Masuda H et al. Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother 2003; 9: 195-200.
9. CDC. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 433-5.
10. Couzin-Frankel J. Swine flu outbreak. What role for antiviral drugs? Science 2009; 324: 705.
11. Scalera NM, Mossad SB. The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus. Postgrad Med 2009; 121: 43-7.
12. Belser JA, Lu X, Szretter KJ et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196: 1493-9.
13. Chan RW, Chan MC, Wong AC et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother 2009; 53: 3935-41.
14. Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50: 1470-9.
15. Triana-Baltzer GB, Gubareva LV, Klimov AI et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS ONE 2009; 4: e7838.
16. Triana-Baltzer GB, Gubareva LV, Nicholls JM et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 2009; 4: e7788.
17. Triana-Baltzer GB, Babizki M, Chan MC et al. DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. J Antimicrob Chemother 2010; 65: 275-84.
18. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996; 40: 40-6.
19. Hayden FG, Cote KM, Douglas RG Jr. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother 1980; 17: 865-70.
20. Hoffmann E, Stech J, Guan Y et al. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001; 146: 2275-89.
21. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993; 67: 2972-80.
22. Ha Y, Stevens DJ, Skehel JJ et al. X-ray structure of the hemagglutinin of a potential H3 avian progenitor of the 1968 Hong Kong pandemic influenza virus. Virology 2003; 309: 209-18.
23. Wang Q, Tian X, Chen X et al. Structural basis for receptor specificity of influenza B virus hemagglutinin. Proc Natl Acad Sci USA 2007; 104: 16874-9.
24. Varghese JN, Epa VC, Colman PM. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 1995; 4: 1081-7.
25. DeLano WL. The PyMOL Molecular Graphics System. http://www.pymol.org. DeLano Scientific, 2002.
26. Gubareva LV, Nedyalkova MS, Novikov DV et al. A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site. J Gen Virol 2002; 83: 2683-92.
27. Kobasa D, Kodihalli S, Luo M et al. Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J Virol 1999; 73: 6743-51.
28. McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47: 2264-72.
29. Matrosovich M, Tuzikov A, Bovin N et al. Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol 2000; 74: 8502-12.
30. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69: 531-69.
31. Air GM, Laver WG. The neuraminidase of influenza virus. Proteins 1989; 6: 341-56.
32. Belser JA, Blixt O, Chen LM et al. Contemporary North American influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. Proc Natl Acad Sci USA 2008; 105: 7558-63.
33. Kumari K, Gulati S, Smith DF et al. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J 2007; 4: 42.
34. Stevens J, Blixt O, Glaser L et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 2006; 355: 1143-55.
35. Stevens J, Blixt O, Tumpey TM et al. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006; 312: 404-10.
36. Stevens J, Blixt O, Chen LM et al. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol 2008; 381: 1382-94.
37. Hatakeyama S, Sakai-Tagawa Y, Kiso M et al. Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol 2005; 43: 4139-46.
38. Matrosovich M, Matrosovich T, Carr J et al. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77: 8418-25.
39. Barnett JM, Cadman A, Burrell FM et al. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999; 265: 286-95.
40. Baum EZ, Wagaman PC, Ly L et al. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antiviral Res 2003; 59: 13-22.
41. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 2007; 74: 159-62.
42. Blick TJ, Tiong T, Sahasrabudhe A et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995; 214: 475-84.
43. Blick TJ, Sahasrabudhe A, McDonald M et al. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 1998; 246: 95-103.
44. Cheam AL, Barr IG, Hampson AW et al. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antiviral Res 2004; 63: 177-81.
45. Giannecchini S, Campitelli L, Bandini G et al. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules. Virus Res 2007; 129: 241-5.
46. Gubareva LV, Bethell R, Hart GJ et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70: 1818-27.
47. Gubareva LV, Robinson MJ, Bethell RC et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71: 3385-90.
48. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72: 2456-62.
49. Molla A, Kati W, Carrick R et al. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol 2002; 76: 5380-6.
50. Nedyalkova MS, Hayden FG, Webster RG et al. Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA. J Infect Dis 2002; 185: 591-8.
51. Smee DF, Sidwell RW, Morrison AC et al. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. Antiviral Res 2001; 52: 251-9.
52. Tai CY, Escarpe PA, Sidwell RW et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42: 3234-41.
53. Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 2002; 46: 3809-16.
54. Gooskens J, Jonges M, Claas EC et al. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 2009; 301: 1042-6.
55. Hurt AC, Holien JK, Parker MW et al. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009; 69: 2523-31.
56. Chandrasekaran A, Srinivasan A, Raman R et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol 2008; 26: 107-13.
57. Yamada S, Suzuki Y, Suzuki T et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 2006; 444: 378-82.
58. Liu C, Air GM. Selection and characterization of a neuraminidaseminus mutant of influenza virus and its rescue by cloned neuraminidase genes. Virology 1993; 194: 403-7.
59. Yang P, Bansal A, Liu C et al. Hemagglutinin specificity and neuraminidase coding capacity of neuraminidase-deficient influenza viruses. Virology 1997; 229: 155-65.
60. Bantia S, Ghate AA, Ananth SL et al. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob Agents Chemother 1998; 42: 801-7.
61. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 2001; 49: 147-56.
62. Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med Virol 2000; 10: 45-55.